Avoid the Extremes<br />By Rev Shark<br />RealMoney.com Contributor<br />8/23/2010 8:46 AM EDT <br /><br /><br />All empty souls tend toward extreme opinions. <br />-- William Butler Yeats<br /><br />We are kicking off the week with one of those routine Monday-morning gap-up opens, but the big picture is definitely murky and muddled. After a perfunctory low-volume oversold bounce last week, we rolled back over on Thursday and are now trying to hold above the little underlying support we have left. <br /><br />The action lately hasn't been especially bad, but volume has been extremely light and the trading very random. A small group of stocks, mostly in agriculture and the cloud computing sector (such as Salesforce.com (CRM) , VMware (VMW) and F5 (FFIV) ), have been leading lately, but the pockets of momentum have been quite limited. The vast majority of charts just aren't very interesting either as longs or as shorts. <br /><br />The most positive thing about a market like this is that if you are open-minded and flexible, you are likely to find some good trading. This is not a good environment in which to be overly bullish or bearish, because you are likely to be whipsawed. The bulls, who were convinced that our little oversold bounce last week was the start of a new uptrend, were punished on Thursday, but the overly aggressive bears, who are sure the end is near, are being squeezed this morning. <br /><br />Market players are often pushed by the financial media and market gurus to have a strong view of the market. The media prefer people who have extreme opinions about things because it creates controversy. It may make for good TV, but we are often much better off if we just go with the flow and trade what is in front of us. You don't need to have a strong opinion if you simply embrace what is happening right now. <br /><br />There is no question that the overall technical picture of the market isn't very favorable right now. Volume is extremely light, we have negative seasonality kicking in and there aren't many potentially positive news catalysts on the horizon. The S&P 500 has minor technical support around 1060 or so, but then the next stop is the lows of the year around 1010. <br /><br />Despite the poor technical picture, there have been signs of underlying support from dip-buyers. They are helping to hold us up so far, and plenty of market players are optimistic about the generally good earnings reports we have had and are looking to buy their favorites on weakness. <br /><br />It is a good market for those who are flexible and are sticking with short-term trades. We can look at some longer term trades when the technical condition of the major indices improves, but for now it's important to keep time frames tight and to be open-minded. Extreme views aren't going to make you money when the action is random and bumpy. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: WCRX +1.4%. <br /><br />M&A news: PAR +36.9% (HPQ proposes to acquire 3PAR for $24 per share in cash, a 33% premium to DELL's $18.00 cash bid/Friday's closing price), POT +1.6% and BHP +1.2% (Potash Board of Directors rejects BHP Billiton's unsolicited offer; also reports out over the weekend that the co received inquiries related to holding talks).<br /><br />Select financial related names showing strength: PMI +2.6%, STD +2.5%, BCS +1.6%, ING +1.5%, AIB +1.4%, RBS +1.4%, UBS +1.2%, NBG +1.1%, C +1.1%, HBAN +0.9%. <br /><br />Select metals/mining stocks trading higher: GBG +2.9% (provides mineral resource update for its Burnstone Gold project in South Africa; increased the overall resources ), RTP +1.9%, AA +1.2%, CLF +1.2%, GOLD +0.6%, . <br /><br />Select computer service PAR peers are up in sympathy: ISLN +12.2%, CML +10.0%, CVLT +4.9%. <br /><br />Select European drug names trading higher: GSK +1.6%, SNY +1.4%<br /><br />Other news: SCOK +15.6% (still checking), AVII +7.8% (Nature Medicine Publishes AVI BioPharma Preclinical Studies Demonstrating Post-Exposure Efficacy of PMOplus Oligomers Against Ebola and Marburg Viruses), MTXX +5.9% (Hearing strength attributed to boutique firm upgrade), HP +3.2% (ticking higher on positive mention in financial newspaper), CAGC +2.9% (still checking), HBC +0.8% (seeing early strength; reports out over the weekend suggest the co may buy stake in Old Mutual's Nedbank). <br /><br />Analyst comments: LOW +2.2% (upgraded to Buy from Neutral at Goldman), FSLR +1.8% (upgraded to Buy from Neutral at UBS).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: SAFM -5.0%<br /><br />M&A news: HPQ -0.6% (HPQ proposes to acquire 3PAR for $24 per share in cash, a 33% premium to DELL's $18.00 cash bid/Friday's closing price). <br /><br />Other news: JAZZ -22.2% (lower following Friday's announcement that FDA voted 20-2 that the benefit/risk balance did not support the approval of JZP-6), CPIX -8.6% (announces extension of FDA review of Acetadote supplemental new drug application), FRO -2.2% (still checking), . <br /><br />Analyst comments: UTA -3.7% (downgraded to Hold at Brean Murray), BIDU -1.3% (Hearing downgraded at Deutsche Bank).